Identifying new biomarkers for clear cell renal cell carcinoma
Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma
This study is trying to find new markers in the blood that can help doctors diagnose clear cell kidney cancer earlier and better by comparing them in patients with the cancer and healthy people.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Sex | All |
| Sponsor | Qianfoshan Hospital Academic / other |
| Locations | 1 site (Jinan) |
| Trial ID | NCT05214885 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify novel biomarkers related to hypoxia and metabolism in patients with clear cell renal cell carcinoma (ccRCC). By analyzing the expression of specific molecules, such as carbonic anhydrase IX and others, the study seeks to improve early diagnosis and understanding of ccRCC. The research involves comparing these biomarkers in ccRCC patients to healthy controls to establish their potential as reliable diagnostic tools. No interventions are required from participants, making it a non-invasive study.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with clear cell renal cell carcinoma and healthy individuals matched by age and sex.
Not a fit: Patients with other types of tumors or significant renal or systemic diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and better management of clear cell renal cell carcinoma.
How similar studies have performed: Preliminary studies have suggested that similar approaches to identifying biomarkers in ccRCC have shown promise, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The age and sex of the healthy control group were matched with that of ccRCC patient group. There was no tumor in the kidney or other parts of the body, and no tumor in the blood system. The healthy control group did not have any renal benign diseases, such as kidney stones, diabetic nephropathy, inflammation, and uremia. There are no inflammatory diseases in other parts of the body; the functions of the liver, kidney, and heart were normal. Exclusion Criteria: * The volunteer has tumors in the kidney or other parts of the body, or blood system tumors; The volunteer has benign kidney diseases, such as kidney stones, diabetic nephropathy, nephritis and uremia, etc; The patient has inflammatory disease elsewhere. If the volunteer has any one of the above diseases, it shall be excluded.
Where this trial is running
Jinan
- The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital — Jinan, China (Recruiting)
Study contacts
- Principal investigator: Li Zhang, Dr. — The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital
- Study coordinator: Li Zhang, Dr.
- Email: maggie_zhangli@139.com
- Phone: +86-531-89269680
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.